北美顏面注射劑市場:2012年

北美顏面注射劑市場:2012年 是由出版商Millennium Research Group在2011年12月所出版的。 這份英文市場調查報告書價格從美金6995起跳。

簡介

以肉毒桿菌(BTX)、皮膚注射劑產品為代表性產品的北美顏面注射劑市場，在2008年後半開始的不景氣下大幅滑落，之後漸漸恢復原來的成長步調，一般預測玻尿酸及皮膚填充劑的各個領域，在到2016年這段預測期間將在旺盛的需求下呈現高度穩定的成長。

本報告探討北美顏面注射劑市場實際狀況，彙整由周全的預備調查所得到的基礎資訊直接採訪業界相關人士得來的驗証結果，為您概述為以下內容。

目錄

圖表一覽

摘要整理

第1章 臨床環境

• 背景
• 診斷與症狀模式
• 治療方法概要
  • 臉部注射治療
  • 競爭療法
  • 新興的競爭療法·技術
• 臨床指南
• 各國市場概要
  • 加拿大
    • 人口動態和經濟
    • 保健系統
    • 法規環境
    • 製造與流通
  • 美國
    • 人口動態和經濟
    • 保健系統
    • 法規環境

第2章 產品

• 概要
  • 對象產品
  • 差異化特徵
• 肉毒桿菌
  • 功能
  • 表示功效
  • 新興的新產品
• 皮膚填充劑
  • 功能
  • 差異化特徵
  • 表示功效
  • 新興的新產品
• 新興的新技術

第3章 臨床實驗

• 完成的臨床實驗
• 進行中的臨床實驗

第4章 品牌及競爭分析

• 概要
  • 競爭概況
  • 詳述競爭環境
  • 市場佔有率
  • 最近的現象
• 肉毒桿菌市場
• 皮膚填充劑市場

第5章 市場預測

• 概要
  • 市場概況
  • 詳述市場情形
• 肉毒桿菌市場
• 皮膚填充劑市場

附錄

目錄

Abstract

The North American facial injectable market - comprising revenues from the sale of botulinum toxin (BTX) and dermal filler products, including hyaluronic acid (HA) dermal fillers, and semi- and nonpermanent non-HA fillers - experienced a large decline during the recession, starting in late 2008, but have since experienced a strong recovery. Through 2016, both the BTX and dermal filler markets will experience high growth as patients continue to demand aesthetic procedures. The entry of Merz Pharmaceutical's Belotero and Xeomin (dermal filler and BTX products, respectively) in 2011 is expected to alter the competitive landscape because physicians and patients will have a larger range of products to choose from. Competitive pricing pressures, heightened by Merz Pharmaceutical's entry into the market, will limit market growth. Nevertheless, increasing patient aesthetic consciousness and the resultant demand for facial injectable procedures will drive unit sales, thus facilitating the expansion of both the BTX and dermal filler markets. The US market will continue to account for the majority of facial injectable sales compared to Canada due to a larger overall population and a more aesthetically conscious population. Overall, the North American facial injectable market will experience steady and high growth over the forecast period as the number of patients demanding for the treatments continues to rise.

METHODOLOGY

RESEARCH METHODOLOGY

This report uses a number of methodologies to gather and present data and analysis. At the outset, a large survey of secondary sources is conducted. These sources act as the basis for the primary research stage, which builds and enhances the quantitative and qualitative attributes of the early research.

Secondary sources include

• Government sources:
  • Securities and Exchange Commission filings
  • Food and Drug Administration and patent filings
  • US Census Bureau
  • National Center for Health Statistics
• Aesthetic (facial injectable) companies:
  • Annual reports, product brochures, corporate profiles, etc.
• Internal databases and reports:
  • Previous reports on similar/related sources
• General Internet searches, medical literature, and newspaper/magazine searches:
  • Identifying various centers of specialization and articles that might provide leads for primary research

The secondary research stage builds the foundation for the primary research.

The primary research methodology has four steps:

Step 1: The first step involves an impartial scan of all the information gathered during the secondary research stage to determine its utility based on the specific requirements of this report. Each piece of information is either discarded or marked as high- or low-priority and then organized appropriately as determined by the structure and sectioning of the report.

Step 2: At this stage, early assumptions are formed as to the implications of the information for the various facial injectable market segments. These assumptions are then used to determine hypotheses using both inductive and deductive approaches. On the quantitative front, these hypotheses result in full historical and projected market data sets (market sizes - unit sales, average selling prices [ASPs], and revenues - as well as market shares).

Step 3: At this stage, the research is in position for its most important primary phase - expert interviews. Throughout the secondary research phase, industry and medical experts are identified.

These experts are then contacted by telephone and asked to participate in interviews on recent trends and developments in the industry. Interviews are either conducted at the time of the initial call or scheduled at the convenience of the expert. Interview questions are tailored to the expertise of each particular interviewee, although in most cases, the most important questions are asked of all experts.

The questions are largely based on the assumptions and hypotheses developed in Step 2, which are then augmented, discarded, or adjusted based on the views and positions put forth. Attempts are made, whenever possible, to cross-check the views of various experts against each other and to reach positions of consensus on issues and market numbers.

In addition, 4 plastic surgeons are interviewed. Physicians are asked to comment on various issues/trends, both in their own practice and in the overall market. The responses provided are then used to strengthen or augment the assumptions and hypotheses developed during the primary research phase.

Step 4: The final stage of primary research involves individual and group analysis by Millennium Research Group. All research results are assessed and cross-checked thoroughly to determine their validity, relevance, and weight. From this process, qualitative conclusions are reached and data points finalized.

MARKETRACK METHODOLOGY

Millennium Research Group's Marketrack methodology involves recruiting medical personnel (e.g. plastic surgeons, dermatologists, other aesthetic practitioners) responsible for the management of medical equipment and procedures to participate by providing procedure volumes, device usage data, and brand-level pricing information on an ongoing basis.

FORECAST METHODOLOGY

In addition to the research methodology outlined above, the following “bottom-up” methodology is used to develop forecast assumptions for the report.

A comprehensive breakdown of various facial injectable procedures and unit sales is prepared using data from several sources, including professional associations, government statistics, and private research/media sources. Industry experts and practitioners are consulted to ensure accuracy and verify observed trends. As a cross-check, total industry revenues available through annual reports and other sources are compared against modeled industry revenues.

Using the best estimates of industry experts, practitioners, private research/media sources, and inhouse experts, year-by-year growth rates and ASPs are applied individually to each subcategory to derive forecasts. These estimates are cross-checked by industry experts (marketing managers, product managers, CEOs, etc.) and further refined.

Overall findings are compared against market and procedure forecasts published by other sources to ensure reasonable estimates.

Companies mentioned in this report:

• Alcon
• Allergan
• Anika Therapeutics
• Anteis
• Clarion Medical
• Coapt Systems
• Fibrocell Science
• Ipsen
• Laboratoires TEOXANE
• Medicis Pharmaceutical
• Mentor (a Johnson & Johnson company)
• Merz Pharmaceuticals
• Polymekon
• Prollenium Medical Technologies
• Q-Med (acquired by Galderma)
• Revance Therapeutics
• Rofil Medical International
• Sanofi
• Solstice Neurosciences
• Suneva Medical
• US WorldMeds
• Valeant Pharmaceuticals

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

1.0. CLINICAL LANDSCAPE

• 1.1. Background
• 1.2. Diagnosis and Referral Patterns
• 1.3. Procedure Overview
  • 1.3.1. Facial Injectable Procedures
  • 1.3.2. Competing Treatments
  • 1.3.3. Emerging Competing Treatments and Technologies
• 1.4. Clinical Guidelines
• 1.5. Reimbursement Guidelines
• 1.6. Country Overview
  • 1.6.1. Canada
    • 1.6.1.1. Demographics and Economy
    • 1.6.1.2. Health Care System
    • 1.6.1.3. Regulatory Environment
    • 1.6.1.4. Manufacturing and Distribution
  • 1.6.2. US
    • 1.6.2.1. Demographics and Economy
    • 1.6.2.2. Health Care System
    • 1.6.2.3. Regulatory Environment

2.0. PRODUCTS

• 2.1. Overview
  • 2.1.1. Products Covered
  • 2.1.2. Differentiating Features
• 2.2. Botulinum Toxins
  • 2.2.1. Functions
  • 2.2.2. Labeled Indications
  • 2.2.3. Emerging Products
• 2.3. Dermal Fillers
  • 2.3.1. Functions
    • 2.3.1.1. Hyaluronic Acid Fillers
    • 2.3.1.2. Other Dermal Fillers
  • 2.3.2. Differentiating Features
  • 2.3.3. Labeled Indications
  • 2.3.4. Emerging Products
• 2.4. Emerging Technologies

3.0. CLINICAL TRIALS

• 3.1. Completed Clinical Trials
• 3.2. Ongoing Clinical Trials

4.0. BRANDS AND COMPETITIVE ANALYSIS

• 4.1. Overview
  • 4.1.1. Competitive Snapshot
  • 4.1.2. Detailed Competitive Landscape
  • 4.1.3. Market Shares
  • 4.1.4. Recent Events
• 4.2. Botulinum Toxin Market
  • 4.2.1. Competitive Snapshot
  • 4.2.2. Current Market Shares
• 4.3. Dermal Filler Market
  • 4.3.1. Competitive Snapshot
  • 4.3.2. Current Market Shares

5.0. MARKET OUTLOOK

• 5.1. Overview
  • 5.1.1. Market Snapshot
  • 5.1.2. Detailed Market Overview
• 5.2. Botulinum Toxin Market
  • 5.2.1. Market Snapshot
  • 5.2.2. Detailed Market Overview
• 5.3. Dermal Filler Market
  • 5.3.1. Market Snapshot
  • 5.3.2. Detailed Market Overview
    • 5.3.2.1. Hyaluronic Acid Dermal Filler Market
    • 5.3.2.2. Other Dermal Filler Market

APPENDIX A: METHODOLOGY

APPENDIX B: MRG ACRONYMS AND INITIALISMS

APPENDIX C: BIBLIOGRAPHY

LIST OF FIGURES AND TABLES

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

• Figure 1: Facial Injectable Market, North America (US$), 2010 - 2016
• Table 1: Facial Injectable Market Landscape, North America (US$), 2011 and 2016
• Table 2: Facial Injectable Market Leaders, by Product Type and Revenue, North America, 2011
• Table 3: Most Promising Emerging Technologies in the Facial Injectable Market, North America, 2011 - 2016
• Table 4: Expected Key Events in the Facial Injectable Market, North America, 2012 - 2016
• Table 5: Factors Impacting the Facial Injectable Market, by Product Type, North America, 2011 - 2016
• Table 6: Companies Mentioned in This Report
• Table 7: Key Report Updates, 2012

1.0 CLINICAL LANDSCAPE

• Table 8: Areas of the Face Commonly Treated with Facial Injectables
• Table 9: Common Facial Injectable Indications, by Product Type, North America, 2011
• Table 10: Volume of Facial Injectable Product per Procedure, by Product
• Table 11: Competing Treatments, North America, 2011
• Table 12: Facial Injectable Treatment Guidelines, by Product Type, North America
• Table 13: Key Health and Economic Indicators, Canada, 2011
• Table 14: Key Health and Economic Indicators, US, 2011

2.0 PRODUCTS

• Table 15: Facial Injectable Market, by Product Type, North America
• Table 16: Advantages and Disadvantages of Facial Injectables, by Product Type
• Table 17: BTX Functions, by Applicable Serotypes
• Table 18: Common Cosmetic BTX Products, North America, 2011
• Table 19: Approved BTX Products, North America, 2011
• Table 20: Emerging Products in Development for the BTX Market, North America, 2011 - 2016
• Table 21: Dermal Filler Functions, by Product Subtype and Product Feature
• Table 22: Dermal Filler Functions, by Product Type
• Table 23: Other Dermal Filler Functions, by Product Type
• Table 24: Advantages and Disadvantages of Dermal Fillers, by Material and Product Features

3.0 CLINICAL TRIALS

• Table 25: Summary of NT 201 in Comparison with Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines (Head2Head)
• Table 26: Summary of Safety and Efficacy of Two Types of Botulinum Toxin Type A for the Treatment of Glabellar Lines
• Table 27: Summary of Safety and Effectiveness of Aquamid as Compared to Restylane for the Aesthetic Treatment of Nasolabial Folds
• Table 28: Summary of Safety and Efficacy of JUVEDERM Injectable Gel with Lidocaine
• Table 29: Summary of Solid State Hyaluronic Acid: A Novel Delivery System to Enable the Precise and Rapid Treatment of Fine and Deep Wrinkles
• Table 30: Summary of EMERVEL Classic Lidocaine Versus JUVEDERM Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds
• Table 31: Summary of JUVEBTX
• Table 32: Summary of Volume Restoration of the Aging Midface with Sculptra Aesthetic

4.0 BRANDS AND COMPETITIVE ANALYSIS

• Table 33: Leading Competitors in the Facial Injectable Market, by Product Type, as a % of Total, North America, 2011
• Table 34: Recent Events in the Facial Injectable Market, North America, 2011
• Table 35: Leading Competitors in the BTX Market, by Country, as a % of Total, North America, 2011
• Table 36: Leading Competitors in the Dermal Filler Market, by Material, as a % of Total, North America, 2011
• Table 37: Leading Competitors in the HA Filler Market, by Country, as a % of Total, North America, 2011
• Table 38: Leading Competitors in the Other Dermal Filler Market, by Country, as a % of Total, North America, 2011

5.0 MARKET OUTLOOK

• Figure 2: Facial Injectable Market, by Product Type, North America (US$), 2010 - 2016
• Table 39: Factors Impacting the Facial Injectable Market, by Product Type, North America, 2011 - 2016
• Table 40: Facial Injectable Procedures, by Product Type, North America, 2010 - 2016
• Table 41: Facial Injectable Procedures, by Country, North America, 2010 - 2016
• Table 42: Facial Injectable Procedures, by Anatomy and Product Type, North America, 2011
• Table 43: Facial Injectable Procedures, by Anatomy and Country, North America, 2011
• Table 44: Facial Injectable Market, by Product Type, North America (US$), 2010 - 2016
• Table 45: Facial Injectable Market Growth, by Product Type, North America, 2011 - 2016
• Table 46: Facial Injectable Market, by Product Type, as a % of Total, North America, 2010 - 2016
• Table 47: Facial Injectable Market, by Country, North America (US$ and CA$), 2010 - 2016
• Table 48: Facial Injectable Market Growth, by Country, North America, 2011 - 2016
• Table 49: Facial Injectable Market, by Country, as a % of Total, North America, 2010 - 2016
• Figure 3: BTX Market, North America (US$), 2010 - 2016
• Table 50: BTX Procedures, by Country, North America, 2010 - 2016
• Table 51: BTX Procedures, by Anatomy and Country, as a % of Total, North America, 2011
• Table 52: BTX Market, by Country, North America (US$ and CA$), 2010 - 2016
• Table 53: BTX Market Growth, by Country, North America, 2011 - 2016
• Table 54: BTX Market, by Country, as a % of Total, North America, 2010 - 2016
• Figure 4: Dermal Filler Market, by Material, North America (US$), 2010 - 2016
• Table 55: Dermal Filler Procedures, by Country, North America, 2010 - 2016
• Table 56: Dermal Filler Market, by Material, North America (US$), 2010 - 2016
• Table 57: Dermal Filler Market Growth, by Material, North America, 2011 - 2016
• Table 58: Dermal Filler Market, by Material, as a % of Total, North America, 2010 - 2016
• Table 59: Dermal Filler Market, by Country, North America (US$ and CA$), 2010 - 2016
• Table 60: Dermal Filler Market Growth, by Country, North America, 2011 - 2016
• Table 61: Dermal Filler Market, by Country, as a % of Total, North America, 2010 - 2016
• Table 62: HA Dermal Filler Procedures, by Anatomy and Country, as a % of Total, North America, 2011
• Table 63: HA Dermal Filler Procedures, by Country, North America, 2010 - 2016
• Table 64: HA Dermal Filler Market, by Country, North America (US$ and CA$), 2010 - 2016
• Table 65: HA Dermal Filler Market Growth, by Country, North America, 2011 - 2016
• Table 66: HA Dermal Filler Market, by Country, as a % of Total, North America, 2010 - 2016
• Table 67: Other Dermal Filler Procedures, by Anatomy and Country, as a % of Total, North America, 2011
• Table 68: Other Dermal Filler Procedures, by Country, North America, 2010 - 2016
• Table 69: Other Dermal Filler Market, by Country, North America (US$ and CA$), 2010 - 2016
• Table 70: Other Dermal Filler Market Growth, by Country, North America, 2011 - 2016
• Table 71: Other Dermal Filler Market, by Country, as a % of Total, North America, 2010 - 2016

APPENDIX A: METHODOLOGY

• Table 72: Average Currency Exchange Rates, 2011

APPENDIX B: MRG ACRONYMS AND INITIALISMS

• MRG Acronyms and Initialisms

APPENDIX C: BIBLIOGRAPHY

相關商品